<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Facts Views Vis Obgyn</journal-id><journal-id journal-id-type="iso-abbrev">Facts Views Vis Obgyn</journal-id><journal-id journal-id-type="pmc">PMC4788335</journal-id><journal-title-group><journal-title>Facts, Views &#x00026; Vision in ObGyn</journal-title></journal-title-group><issn pub-type="ppub">2032-0418</issn><publisher><publisher-name>Universa Press</publisher-name><publisher-loc>Wetteren, Belgium</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28721181</article-id><article-id pub-id-type="pmc">5506766</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Paper</subject></subj-group></article-categories><title-group><article-title>Adding sildenafil vaginal gel to clomiphene citrate in infertile women with prior clomiphene citrate failure due to thin endometrium: a prospective self-controlled clinical trial</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Fetih</surname><given-names>AN</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Habib</surname><given-names>DM</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Abdelaal</surname><given-names>II</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Hussein</surname><given-names>M</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Fetih</surname><given-names>GN</given-names></name><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name><surname>Othman</surname><given-names>ER</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><aff id="aff1">Department of Obstetrics and Gynecology, Faculty of Medicine, Assiut University, Egypt</aff><aff id="aff2">Department of Pharmaceutics, Faculty of Pharmacy, Assiut University, Egypt</aff></contrib-group><author-notes><corresp id="cor1">Correspondence at: <email>essamrash@yahoo.com</email></corresp></author-notes><pub-date date-type="pub" publication-format="print"><month>3</month><year>2017</year></pub-date><pub-date date-type="pub" publication-format="electronic" iso-8601-date="2017-03-30"><day>30</day><month>3</month><year>2017</year></pub-date><volume>9</volume><issue>1</issue><fpage>21</fpage><lpage>27</lpage><permissions><copyright-statement>Copyright &#x000a9; 2017 Facts, Views &#x00026; Vision</copyright-statement><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec><title/><p>We aimed to investigate the effect of adding sildenafil vaginal gel to clomiphene citrate (CC) in infertile women with prior CC failure.</p></sec><sec><title>Methods</title><p>This is a self- controlled clinical trial. Women with CC failure (in prior 5 cycles) and thin endometrium were recruited (N = 42). In their 6th (CC only) cycle, women continued on CC 100 mg/ day for 5 days, and had measurement of endometrial thickness and Doppler assessment of uterine arteries on day of HCG administration. In the 7th cycle, women (N = 36) were given usual dose of CC supplemented with sildenafil vaginal gel (5 gm, containing 50 mg sildenafil) twice daily from cycle day 8 to day of HCG administration. Endometrial thickness and uterine artery Doppler were measured on the day of HCG injection.</p></sec><sec><title>Results:</title><p>In the 7th (CC + sildenafil vaginal gel) cycle, endometrial thickness was significantly higher than in the 6th (CC only) cycle (9.3 mm +/- 3.1mm versus 6.6 mm +/- 1.4 mm, respectively, P = &#x0003c; 0.001). Uterine artery pulsatility index dropped from 2.4 +/- 0.8 in 6th cycle to 1.6 +/- 1.3 in 7th cycle (P = 0.002). Clinical pregnancy rate increased but numbers were too small (only 3 pregnancies). </p></sec><sec><title>Conclusion</title><p>Sildenafil vaginal gel significantly increased endometrial thickness and uterine blood flow, and may improve pregnancy rate in patients with CC failure due to thin endometrium. Mucoadhesive vaginal gel formulation allowed shorter duration of sildenafil application, and less frequent daily dosing.</p></sec></abstract><kwd-group kwd-group-type="author"><title>Key words</title><kwd>Anovulation</kwd><kwd>clomiphene citrate</kwd><kwd>endometrium</kwd><kwd>endometrial thickness</kwd><kwd>infertility</kwd><kwd>sildenafil vaginal gel</kwd></kwd-group></article-meta></front><body><sec sec-type="introduction"><title>Introduction</title><p>Anovulation is a cause of infertility in 20% of the cases (<xref rid="B46" ref-type="bibr">Weiss et al., 2014</xref>). Around 85% of the women with anovulatory infertility have normal gonadotropin levels and are classified as type-2 anovulation according to the world Health Organization classification (<xref rid="B43" ref-type="bibr">The ESHRE Capri Workshop Group, 2012</xref>). Most of these cases are the result from polycystic ovarian syndrome (PCOS) (<xref rid="B10" ref-type="bibr">Brown et al., 2009</xref>).</p><p>Guidelines state that clomiphene citrate (CC) is the first line treatment for ovulation induction in women with type 2 anovulation or polycystic ovaries (<xref rid="B44" ref-type="bibr">The Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group, 2008</xref>; <xref rid="B10" ref-type="bibr">Brown et al., 2009</xref>; <xref rid="B43" ref-type="bibr">The ESHRE Capri Workshop Group, 2012</xref>). CC is a non-steroidal compound that works as anti-oestrogen. It blocks oestrogen receptors at the hypothalamus, releasing it from negative feedback, and augmenting its release of GnRH. Subsequently, pituitary production of gonadotropins is increased resulting in follicular growth, and ovulation (<xref rid="B6" ref-type="bibr">Balen, 2013</xref>). Ovulation rates with CC approach 70- 85% per cycle, whereas cumulative pregnancy rates in a 6-month period is 40- 70% (<xref rid="B15" ref-type="bibr">Eijkemans et al., 2003</xref>; <xref rid="B45" ref-type="bibr">Van Santbrink and Fauser, 2006</xref>).</p><p>About 15% of anovulatory women do not respond to CC (<xref rid="B10" ref-type="bibr">Brown et al., 2009</xref>). This is identified as clomiphene citrate resistance. On the other hand, clomiphene citrate failure refers to another subset of women who do not get pregnant despite achieving ovulation after CC treatment (<xref rid="B44" ref-type="bibr">The Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group, 2008</xref>; <xref rid="B6" ref-type="bibr">Balen, 2013</xref>). Management of women with clomiphene citrate resistance or failure consists of gonadotropin induction of ovulation or laparoscopic ovarian drilling in PCOS (<xref rid="B45" ref-type="bibr">Van Santbrink and Fauser, 2006</xref>). Ovulation induction with gonadotropins is expensive, requires frequent monitoring, is associated with higher risk of ovarian hyperstimulation syndrome, and multiple pregnancies (<xref rid="B15" ref-type="bibr">Eijkemans et al., 2003</xref>) Similarly, laparoscopic ovarian drilling is associated with potential damage to ovarian reserve, and possible adhesion formation (<xref rid="B17" ref-type="bibr">Fernandez et al., 2011</xref>). Therefore, analysis of factors leading to clomiphene citrate failure is necessary to make full use of this inexpensive, relatively safe, and effective method of ovulation induction.</p><p>An important cause of clomiphene citrate failure is its anti-estrogenic effect on the endometrium (<xref rid="B14" ref-type="bibr">Dehbashi et al., 2003</xref>; <xref rid="B21" ref-type="bibr">Homburg et al., 2012</xref>). As oestrogen is necessary for endometrial growth during the follicular phase of the cycle, the antiestrogenic effects of CC impair endometrial growth (<xref rid="B1" ref-type="bibr">Amita et al., 2010</xref>). This is evident in endometrial biopsies from women on CC, which show impaired epithelial proliferation, decreased number and diameter of glands, with delayed glandular maturation (<xref rid="B9" ref-type="bibr">Bonhoff et al., 1996</xref>; <xref rid="B37" ref-type="bibr">Sereepapong et al., 2000</xref>). Sonographically, this poor endometrial development is identified as thin endometrium (<xref rid="B29" ref-type="bibr">Nakanrura et al., 1997</xref>).</p><p>Oestrogen mediated growth of the endometrium is dependent on the blood flow to the endometrium (<xref rid="B40" ref-type="bibr">Sher and Fisch, 2002</xref>). It is then logical to think of vasodilator therapies as potential solutions to improve endometrial blood flow and thickness in infertile women with clomiphene citrate failure.</p><p>Sildenafil is a type 5-phosphodiestrase inhibitor that augments vasodilator effect of nitric oxide on vascular smooth muscles by preventing the degradation of cGMP (Sher and Fisch, <xref rid="B41" ref-type="bibr">2000</xref>, <xref rid="B40" ref-type="bibr">2002</xref>). Sildenafil citrate could lead to an improvement in uterine blood flow and, in conjunction with oestrogen, it leads to the oestrogen-induced proliferation of the endometrium (<xref rid="B33" ref-type="bibr">Richter et al., 2007</xref>).</p><p>Few studies addressed the use of sildenafil to increase endometrial thickness in CC stimulated cycles (<xref rid="B24" ref-type="bibr">Malinova et al., 2013</xref>; <xref rid="B13" ref-type="bibr">Das et al., 2009</xref>). In these studies, sildenafil was given as vaginal suppositories and in multiple doses per day. In addition, it was not clear whether the studied population had persistently thin endometrium with prior cycles of CC induction.</p><p>In the present study, we evaluate the use of a new formulation of topical sildenafil (sildenafil vaginal gel) to increase endometrial thickness and uterine blood flow in women with clomiphene citrate failure due to thin endometrium.</p></sec><sec sec-type="materials|methods"><title>Materials and Methods</title><sec><title>Study design</title><p>This is a prospective self-controlled clinical trial. Clinicaltrial.gov identifier is NCT02710981. Assiut University Institutional Review Board approved the study (IRB approval # 00009898)</p></sec><sec><title>Study subjects</title><p>We counselled and recruited 42 infertile women who had been diagnosed with anovulatory infertility, with normal baseline FSH, LH, and free testosterone levels, patent tubes on hysterosalpingography, and normal male semen analysis.</p><p>By the time they were enrolled in the study, all women had already completed 5 ovulatory cycles of CC induction (in a dose of 100 mg/ day in two divided doses starting from day 3 of the cycle for 5 days) but without conception (clomiphene citrate failure) with thin endometrium (&#x0003c;8mm) in at least 3 cycles (<xref rid="B42" ref-type="bibr">Takasaki et al., 2010</xref>). Ovulation was documented sonographically and with day-21 serum progesterone exceeding 5-ng/ ml in all cases. Women who agreed to be enrolled in the study signed an informed consent. All enrolled cases were ovulation induction, not IUI cycles.</p><p>All procedures performed in our study were in accordance with the ethical standards of the institutional and/or national research committee (IRB # 00009898), and with the 1964 Helsinki declaration and its later amendments (Tokyo, 2004). Informed consent was obtained from all individual participants included in the study.</p></sec><sec><title>Exclusion criteria</title><p>Women with major medical problems, male factor infertility, endocrine abnormalities such as hyperprolactinemia or abnormal thyroid functions, prior ovarian or adnexal surgery, or organic pelvic pathology (fibroids, adenomyosis, or congenital uterine anomalies) were not included in the study.</p></sec><sec><title>Intervention</title><p>Sixth cycle (CC only cycle)</p><p>Enrolled cases were asked to continue with CC induction (sanofi-aventis, NJ, USA) at the same dose, for one more cycle (the 6th cycle). When the leading follicle reached 18 mm in diameter, 10000 IU of highly purified HCG (IBSA, Lugano, Switzerland) was prescribed for IM injection. Within the 6th cycle, a gel base, without medicament (vehicle only), was applied vaginally in a dose of 5 gm twice per day, from cycle day 8 to the day of HCG injection. Transvaginal sonography was done to assess endometrial thickness and uterine artery Doppler indices on the day of HCG injection.</p><p>Seventh cycle (CC + Sildenafil vaginal gel cycle)</p><p>Those who didn&#x02019;t conceive on the sixth cycle (41 women) were asked to have an extra (7th) cycle in which they were prescribed the usual dose of CC, in addition to sildenafil vaginal gel. The sildenafil vaginal gel consists of sildenafil acetate as a medicament (Sigma Aldrich, St. Louis, MO, USA) loaded on an in situ gelling system based on two polymers: Pluronic p-127 (BASF Ltd., Ludwigshafen, Germany), and Hydroxy Ethyl Cellulose (Sigma Aldrich, St. Louis, MO, USA). The dose was 5 g gel containing 50 mg sildenafil, applied vaginally twice daily from cycle day 8 to the day of HCG administration. The gel was prepared in collaboration with the department of pharmaceutics, faculty of Pharmacy, Assiut University. Sixty grams of gel were prepared in tubes and every patient was given 12 applicators like that used for administration of vaginal antimycotic creams to use them for applying the gel. Only 36 women agreed to go for the CC + sildenafil vaginal gel cycle, whereas 5 women withdrew consent as they preferred to go for other forms of fertility treatment (gonadotropin induction or IVF/ICSI). No estradiol or any other adjuvants were added in either the 6th or 7th treatment cycles apart from those specified above.</p></sec><sec><title>Evaluation of the study end points</title><p>The ultrasonography machine used in this study is Medison, SonoAce X8. A transvaginal probe with a frequency of 4 to 9 MHz (Medison 3D4-9ES) was used to examine the cases (Samsung-Medison, Seoul, South Korea). Only two experienced operators (MHM, and DMH) evaluated all cases in their 6th and 7th cycles according to the study operational manual.</p><p>During the 6th and 7th cycle, endometrial thickness and uterine artery Doppler assessment were done on the day of HCG administration. Endometrial thickness measurement was done through measuring the maximal distance spanning endometrialmyometrial interphase on each endometrial stripe in a sagittal plane at the region of the uterine fundus. Transvaginal Doppler examination of the pulsatility indices of both uterine arteries was also done during the same visit. Uterine arteries were visualized by colour Doppler lateral to the cervix with the angle of insonation of 30&#x002da;. Pulsatility index (PI), as a measure of resistance to blood flow in uterine arteries, was determined. The mean of PI in both uterine arteries was calculated and recorded.</p><p>Although pregnancy rate was not a primary outcome measure in our study, we detected pregnancy in 3 cases in our cohort of 36 cases of infertile women with clomiphene failure in which sildenafil gel was added as an adjuvant. Pregnancy was diagnosed with a &#x003b2;-HCG value above 100 mIU/ ml, and confirmed later with ultrasound at 7-8 weeks of gestation.</p></sec></sec><sec><title>Statistics</title><p>Data were analysed using SPSS program ver. 17. Clinical and demographic characteristics of the enrolled cases were expressed as mean &#x000b1; standard deviation. Student-t-test was used to compare continuous variables, while Fisher&#x02019;s exact test compared categorical data in the 6th and 7th cycle.</p></sec><sec sec-type="results"><title>Results</title><p>We recruited 42 cases of infertile women, with clomiphene citrate failure (6 ovulatory cycles, with no conception), and thin endometrium (in at least 3 of the CC stimulated cycles). Thirty six patients attempted a seventh cycle with sildenafil vaginal gel as an adjuvant treatment prescribed on cycle day 8 to the day of HCG administration, added to the usual dose of CC used for ovulation induction. Clinical and basic laboratory characteristics of our patient cohort are outlined in <xref ref-type="table" rid="t001">Table I</xref>.</p><table-wrap id="t001" orientation="landscape" position="float"><label>Table I</label><caption><p>&#x02014; Clinical and basic laboratory characteristics of recruited cases</p></caption><table frame="hsides" rules="groups" style="border-collapse: collapse"><thead><tr style="border-top: solid"><td style="border-right: solid" rowspan="1" colspan="1">Characteristic</td><td rowspan="1" colspan="1"><bold>Value</bold></td></tr></thead><tbody><tr style="border-top: solid thin"><td style="border-right: solid" rowspan="1" colspan="1">Age</td><td rowspan="1" colspan="1">26.8 &#x000b1; 2.8 years ,<break/>
(range =22-33 years)</td></tr><tr style="border-top: solid thin"><td style="border-right: solid" rowspan="1" colspan="1">BMI</td><td rowspan="1" colspan="1">29.1 &#x000b1; 4.6 kg/m2</td></tr><tr style="border-top: solid thin"><td style="border-right: solid" rowspan="1" colspan="1">Serum FSH</td><td rowspan="1" colspan="1">4.5 &#x000b1; 1.5 U/ L,<break/>
(patient range = 2.1-7.5)</td></tr><tr style="border-top: solid thin"><td style="border-right: solid" rowspan="1" colspan="1">Serum LH</td><td rowspan="1" colspan="1">9.9 &#x000b1; 4.8 U/ L,<break/>
(patient range =2.0 &#x02013; 20.0)</td></tr><tr style="border-top: solid thin"><td style="border-right: solid" rowspan="1" colspan="1">Serum free testosterone</td><td rowspan="1" colspan="1">0.77 &#x000b1; 0.23 ng/ dl,<break/>
(patient range = 0.4-1.2 ng/ml).</td></tr><tr style="border-top: solid thin"><td style="border-right: solid" rowspan="1" colspan="1">Primary infertility</td><td rowspan="1" colspan="1">N = 26, (72.22 %)</td></tr><tr style="border-top: solid thin"><td style="border-right: solid" rowspan="1" colspan="1">Secondary infertility</td><td rowspan="1" colspan="1">N = 10, (27.77%)</td></tr><tr style="border-top: solid thin"><td style="border-right: solid" rowspan="1" colspan="1">Duration of infertility</td><td rowspan="1" colspan="1">4.3 &#x000b1;1.2 years<break/>
Range: 2 &#x02013; 7 years</td></tr><tr style="border-top: solid thin"><td style="border-right: solid" rowspan="1" colspan="1">Mean parity</td><td rowspan="1" colspan="1">0.3 &#x000b1; 0.1</td></tr></tbody></table></table-wrap><p>Follicular number and size (measured on the day of HCG injection), and number of cycle days until HCG injection were comparable for our cohort of women in their CC only cycle (6th cycle), and the CC + sildenafil vaginal gel cycle (7th cycle). Mean follicular number was 1.3 in the sixth cycle, and 1.4 in the seventh cycle (P value = 0.38). Mean follicular diameter was 17.8 versus 18.8 during the sixth and seventh cycle respectively (P value = 0.096), as seen in <xref ref-type="table" rid="t002">Table II</xref>.</p><table-wrap id="t002" orientation="landscape" position="float"><label>Table II</label><caption><p>&#x02014; Cycle characteristics and pregnancy outcome in the sixth (CC alone) and the seventh (CC + sildenafil vaginal gel) cycles of treatment (N/A: Not applicable due to very few numbers of pregnancies)</p></caption><table frame="hsides" rules="groups" style="border-collapse: collapse"><thead><tr style="border-top: solid"><td style="border-right: solid" rowspan="1" colspan="1"><bold>Cycle characteristics / outcome</bold></td><td style="border-right: solid" rowspan="1" colspan="1"><bold>Sixth cycle (CC only cycle)</bold></td><td style="border-right: solid" rowspan="1" colspan="1"><bold>Seventh cycle (CC + sildenafil vaginal gel cycle)</bold></td><td rowspan="1" colspan="1"><bold>P value</bold></td></tr></thead><tbody><tr style="border-top: solid thin"><td style="border-right: solid" rowspan="1" colspan="1">Number of follicles</td><td style="border-right: solid" rowspan="1" colspan="1">1.3 +/- 0.5</td><td style="border-right: solid" rowspan="1" colspan="1">1.4 +/- 0.6</td><td rowspan="1" colspan="1">0.38</td></tr><tr style="border-top: solid thin"><td style="border-right: solid" rowspan="1" colspan="1">Follicular diameter</td><td style="border-right: solid" rowspan="1" colspan="1">17.8 +/- 1.3</td><td style="border-right: solid" rowspan="1" colspan="1">18.8 +/- 1.7</td><td rowspan="1" colspan="1">0.096</td></tr><tr style="border-top: solid thin"><td style="border-right: solid" rowspan="1" colspan="1">Number of cycle days till HCG injection</td><td style="border-right: solid" rowspan="1" colspan="1">12.0 &#x000b1; 0.2</td><td style="border-right: solid" rowspan="1" colspan="1">11.8 &#x000b1; 0.18</td><td rowspan="1" colspan="1">0.7</td></tr><tr style="border-top: solid thin"><td style="border-right: solid" rowspan="1" colspan="1">Endometrial thickness</td><td style="border-right: solid" rowspan="1" colspan="1">6.6 +/- 1.4 mm</td><td style="border-right: solid" rowspan="1" colspan="1">9.3 +/- 3.1mm</td><td rowspan="1" colspan="1">&#x0003c; 0.001</td></tr><tr style="border-top: solid thin"><td style="border-right: solid" rowspan="1" colspan="1">Uterine artery Pulsatilty index</td><td style="border-right: solid" rowspan="1" colspan="1">2.4 +/- 0.8</td><td style="border-right: solid" rowspan="1" colspan="1">1.6 +/- 1.3</td><td rowspan="1" colspan="1">0.002</td></tr><tr style="border-top: solid thin"><td style="border-right: solid" rowspan="1" colspan="1">Clinical pregnancy rate per cycle</td><td style="border-right: solid" rowspan="1" colspan="1">1 (2.3 %)</td><td style="border-right: solid" rowspan="1" colspan="1">3 (8.4%)</td><td rowspan="1" colspan="1">N/A</td></tr></tbody></table></table-wrap><p>Endometrial thickness showed a statistically significant increase from a value of 6.6 +/- 1.4 mm with CC only treatment during the sixth cycle, to 9.3+/- 3.1mm with CC+ sildenafil vaginal gel in the seventh cycle. P value was &#x0003c;0.001 (<xref ref-type="table" rid="t002">Table II</xref>, <xref ref-type="fig" rid="g001">Fig 1</xref>). As an indicator of uterine blood flow, we used Doppler ultrasound to measure the pulsatility index in both uterine arteries. With the addition of the sildenafil vaginal gel, the uterine artery pulsatility index dropped from 2.4 +/- 0.8 to 1.6 +/- 1.3 (P value = 0.002) indicating a significant reduction in blood flow resistance in the uterine arteries (<xref ref-type="table" rid="t002">Table II</xref>, Fig <xref ref-type="fig" rid="g002">2</xref> &#x00026; <xref ref-type="fig" rid="g003">3</xref>).</p><fig id="g001" orientation="landscape" position="float"><label>Figure 1</label><caption><p>&#x02014; Endometrial thickness on day of HCG injection in a woman on clomiphene citrate plus sildenafil vaginal gel (7th cycle). Note the triple line endometrium</p></caption><graphic xlink:href="FVVinObGyn-9-21-g001"/></fig><fig id="g002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>&#x02014; Doppler waveform on day of hCG injection in a woman under clomiphene citrate treatment (6th cycle)</p></caption><graphic xlink:href="FVVinObGyn-9-21-g002"/></fig><fig id="g003" orientation="portrait" position="float"><label>Figure 3</label><caption><p>&#x02014; Doppler waveform on day of hCG injection in a woman under clomiphene citrate plus sildenafil vaginal gel treatment (7th cycle).</p></caption><graphic xlink:href="FVVinObGyn-9-21-g003"/></fig></sec><sec sec-type="discussion"><title>Discussion</title><p>Using CC in ovulation induction is associated with discrepancy between high ovulation rates (70- 80 %), and low pregnancy rate (only 10- 20 % per cycle) (<xref rid="B5" ref-type="bibr">Badawy et al., 2007</xref>; <xref rid="B4" ref-type="bibr">Badawy et al., 2008</xref>(. This is attributed, at least partly, to poor endometrial growth in CC induction cycles because of its antiestrogenic effect at the endometrium (<xref rid="B26" ref-type="bibr">Mitwally and Casper, 2006</xref>). Various strategies have been attempted to minimize estrogenic antagonist actions of CC but with limited success (<xref rid="B32" ref-type="bibr">Reynolds et al., 2010</xref>).</p><p>In the present study, we tested, for the first time to the best of our knowledge, the effects of sildenafil vaginal gel on endometrial thickness in women with CC failure due to thin endometrium. Our results have shown that sildenafil vaginal gel when added to CC increased endometrial thickness significantly, and improved uterine blood flow. We have also shown an increase in pregnancy rate, although the numbers were too small to draw statistical significance.</p><p>We used a prospective self-controlled clinical trial design for our study. This will eliminate the confounding effects of factors such as age, BMI, race, socioeconomic class, and genetic background, as each case controls for itself (<xref rid="B19" ref-type="bibr">Grady et al., 2007</xref>). In addition, we tested a novel formulation of local sildenafil therapy, which is sildenafil vaginal gel to achieve the desired vasodilator effect at the level of the endometrium, while avoiding systemic side effects.</p><p>Lack of a control group is a limiting factor in our study. However, our recruited subjects are highly selected in terms of having CC failure (6 ovulatory cycles without conception), with thin endometrium in at least 3 cycles). Having thin endometrium in more than one cycle before the intervention emphasizes that this is a persistent trend in this group of patients, and minimizes the likelihood of having a &#x0201c;regression to the mean&#x0201d; effect in the subsequent intervention cycle.</p><p>In agreement with our findings are previous reports that had shown that addition of sildenafil vaginal suppositories to CC induction of ovulation achieved significantly higher endometrial thickness, reduction in uterine artery vascular resistance, and increase in pregnancy rate (<xref rid="B13" ref-type="bibr">Das et al., 2009</xref>; <xref rid="B24" ref-type="bibr">Malinova et al., 2013</xref>). In addition, for women with prior failed IVF/ICSI cycles associated with thin endometrium, using sildenafil vaginal suppositories during their subsequent cycles expanded their endometrial growth, enhanced endometrial blood flow, and improved their pregnancy rates (<xref rid="B41" ref-type="bibr">Sher and Fisch, 2000</xref>; <xref rid="B40" ref-type="bibr">Sher and Fisch 2002</xref>; <xref rid="B33" ref-type="bibr">Richter et al., 2007</xref>; <xref rid="B42" ref-type="bibr">Takasaki et al., 2010</xref>).</p><p>Few studies addressed the relation between endometrial thickness and pregnancy outcome in CC induction cycles. Thin endometrium was associated with non-conception according to some studies (<xref rid="B16" ref-type="bibr">Esmailzadeh and Faramarzi, 2007</xref>; <xref rid="B38" ref-type="bibr">Shahin, 2008</xref>), while in others preovulatory endometrial thickness was of limited predictive ability for pregnancy (<xref rid="B23" ref-type="bibr">Kolibianakis et al., 2004</xref>; <xref rid="B3" ref-type="bibr">Asante et al., 2013</xref>). The reason for these contradicting results may be because of different stimulation protocols (CC alone, CC+ HMG, or IVF/ICSI) (<xref rid="B32" ref-type="bibr">Reynolds et al., 2010</xref>), different cut-off values to define thin endometrium (6, 7, or 8 mm) (<xref rid="B36" ref-type="bibr">Senturk and Erel, 2008</xref>), and variable timing of endometrial thickness measurement (day of HCG administration, or fixed cycle day 10 or 12 (<xref rid="B3" ref-type="bibr">Asante et al., 2013</xref>).</p><p>Despite this debate, endometrial thickness below 7 mm is generally considered suboptimal for pregnancy (<xref rid="B12" ref-type="bibr">Casper, 2011</xref>; <xref rid="B18" ref-type="bibr">Gleicher et al., 2013</xref>). Our study findings confirm the importance of endometrial thickness to achieve pregnancy in CC induction cycles, as CC failure was associated with thin endometrium, whereas the increase in endometrial thickness with sildenafil vaginal gel was associated with an increase in clinical pregnancy rate.</p><p>The mechanism by which clomiphene citrate causes thinning of the endometrium is unknown. Working as an antagonist at the endometrial oestrogen receptor level is a major cause (<xref rid="B26" ref-type="bibr">Mitwally and Casper, 2006</xref>). In addition, diminished uterine and endometrial blood flow in clomiphene citrate stimulated cycles might also play a pathogenic role (<xref rid="B34" ref-type="bibr">Rogers et al., 1998</xref>; <xref rid="B30" ref-type="bibr">Ng EH et al., 2007</xref>). Sakhavar and colleagues could not find significant difference in uterine artery pulsatility or resistive indices among unexplained infertility patients treated with clomiphene citrate, lotrezole, or control women (<xref rid="B35" ref-type="bibr">Sakhavar et al., 2014</xref>). This is taken as a basis for an argument that diminished endometrial blood flow is not a cause for impaired endometrial growth in clomiphene citrate treatment. However, the authors recruited normo-ovulatory women with unexplained infertility. In addition, there was no assessment of endometrial thickness in this study. Consequently, we don&#x02019;t believe that Sakhavar&#x02019;s findings could be extrapolated to anovulatory patients with thin endometrium in repeated clomiphene citrate cycles like the population we recruited to our study.</p><p>On the other hand, <xref rid="B31" ref-type="bibr">Palomba et al. (2006)</xref> reported that PCOS women who ovulated under clomiphene citrate treatment had significantly higher uterine artery resistive index (RI), and increased impedance in endometrial and subendometrial vasculature compared to healthy ovulatory women. Moreover, the pulsatility index of the main uterine arteries during the late follicular phase was reported to be elevated in women under clomiphene citrate treatment compared to women with natural cycles (<xref rid="B22" ref-type="bibr">Hsu et al., 1995</xref>). A study from Japan has shown that uterine perfusion in clomiphene citrate stimulated cycles is significantly lower than natural cycles on the day of ovulation (<xref rid="B28" ref-type="bibr">Nakai et al., 2002</xref>). <xref rid="B27" ref-type="bibr">Miwa et al. (2009)</xref> reported significantly higher resistive index in uterine radial arteries in women with thin endometrium than in women with normal thickness endometrium during different phases of the menstrual cycle. Takasaki and co-workers (<xref rid="B42" ref-type="bibr">2010</xref>) detected improvement in endometrial thickness, and uterine radial artery RI with the use of different vasodilator agents (vitamin E, L-arginine, and vaginal sildenafil acetate) in patients with thin endometrium (&#x0003c; 8 mm), and high radial artery RI. All this body of research evidence supports the notion that there is high uterine vascular resistance and impaired endometrial blood flow in women with clomiphene citrate-associated thin endometrium, and reversing this effect might help to improve endometrial thickness (<xref rid="B20" ref-type="bibr">Gutarra-Vilchez et al., 2014</xref>).</p><p>Vaginal administration of the sildenafil would achieve high concentration at the endometrium, meanwhile avoiding the well-known systemic side effects of sildenafil such as headache, hypotension, and flushing (<xref rid="B39" ref-type="bibr">Shanmugam et al., 2014</xref>). It is worth mentioning that only one of 36 patients who received sildenafil vaginal gel developed headache, with no other side effects reported.</p><p>Previous studies have used vaginal sildenafil in the form of suppositories that were prepared from oral tablets (<xref rid="B40" ref-type="bibr">Sher and Fisch 2002</xref>; <xref rid="B33" ref-type="bibr">Richter et al., 2007</xref>; <xref rid="B13" ref-type="bibr">Das et al., 2009</xref>; <xref rid="B42" ref-type="bibr">Takasaki et al., 2010</xref>; <xref rid="B24" ref-type="bibr">Malinova et al., 2013</xref>). However, there is no registered vaginal suppository form of sildenafil citrate in the market. In addition, vaginal suppositories have poor residence time (<xref rid="B11" ref-type="bibr">Brown et al., 1997</xref>), can be messy, and may not be able to deliver the exact medication dose (<xref rid="B8" ref-type="bibr">Bernkop-Schn&#x000fc;rch and Hornof, 2003</xref>; <xref rid="B7" ref-type="bibr">Baloglu, et al., 2009</xref>). To avoid these disadvantages, we thought of applying sildenafil through a more retensive vaginal administration system (<xref rid="B25" ref-type="bibr">Merabet et al., 2005</xref>).</p><p>In the present study, we used an in-situ gelling drug delivery system for the vaginal administration of sildenafil. Our gel was based on two main polymers mixed together. Pluronic P-127 is a thermosensitive polymer, which changes from aqueous solution to viscous gel at body temperature (<xref rid="B2" ref-type="bibr">Arranja et al., 2014</xref>). Hydroxy Ethyl Cellulose is a mucoadhesive polymer increasing retention time of the gel in the vagina (<xref rid="B7" ref-type="bibr">Baloglu et al., 2009</xref>). These characters of our gel mixture allow more uniform distribution of sildenafil along vaginal absorptive surfaces, and release of the drug at more predictable rate for a longer time period (<xref rid="B7" ref-type="bibr">Baloglu et al., 2009</xref>). It is notable in our study that a significant increase in endometrial thickness, and uterine blood flow occurred with shorter total duration of sildenafil administration (only 5 to 6 days), in comparison to around 10 days in previous studies, which used the sildenafil vaginal suppositories formulation. In addition, we used less frequency dosing per day (two applications of 5 gm gel per day, each containing 50 mg of sildenafil), in comparison to 4 times per day in case of vaginal suppositories, each containing 25 mg/ day.</p><p>In conclusion, we have shown that sildenafil vaginal gel significantly increased endometrial thickness, uterine blood flow and may increase pregnancy rate in anovulatory patients with clomiphene citrate failure due to thin endometrium. The mucoadhesive vaginal gel formulation of sildenafil allowed shorter duration of drug application, and less frequent administration per day.</p></sec></body><back><ack><title>Acknowledgements</title><p>The authors would like to thank the nursing and secretarial staff in the ultrasound unit of Assiut University Women&#x02019;s Health Hospital for their excellent help to complete this work.</p></ack><ref-list><title>References</title><ref id="B1"><label>1</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name><surname>Amita</surname><given-names>M</given-names></name><name><surname>Takahashi</surname><given-names>T</given-names></name><name><surname>Tsutsumi</surname><given-names>S</given-names></name><etal/></person-group><article-title>Molecular mechanism of the inhibition of estradiol-induced endometrial epithelial cell proliferation by clomiphene citrate.</article-title><source>Endocrinology</source><year>2010</year><volume>151</volume><fpage>394</fpage><lpage>405</lpage><pub-id pub-id-type="pmid">19934375</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name><surname>Arranja</surname><given-names>A</given-names></name><name><surname>Schroder</surname><given-names>AP</given-names></name><name><surname>Schmutz</surname><given-names>M</given-names></name><etal/></person-group><article-title>Cytotoxicity and internalization of Pluronic micelles stabilized by core crosslinking.</article-title><source>J Control Release</source><year>2014</year><volume>196</volume><fpage>87</fpage><lpage>95</lpage><pub-id pub-id-type="pmid">25307996</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name><surname>Asante</surname><given-names>A</given-names></name><name><surname>Coddington</surname><given-names>CC</given-names></name><name><surname>Schenck</surname><given-names>L</given-names></name><etal/></person-group><article-title>Thin endometrial stripe does not affect likelihood of achieving pregnancy in clomiphene citrate/intrauterine insemination cycles</article-title><source>Fertil Steril</source><year>2013</year><volume>100</volume><issue>6</issue><fpage>1610</fpage><lpage>1614</lpage><elocation-id>e1</elocation-id><pub-id pub-id-type="pmid">24074755</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name><surname>Badawy</surname><given-names>A</given-names></name><name><surname>Mosbah</surname><given-names>A</given-names></name><name><surname>Shady</surname><given-names>M</given-names></name></person-group><article-title>Anastrozole or letrozole for ovulation induction in clomiphene-resistant women with polycystic ovarian syndrome: a prospective randomized trial.</article-title><source>Fertil Steril</source><year>2008</year><volume>89</volume><fpage>1209</fpage><lpage>1212</lpage><pub-id pub-id-type="pmid">17686479</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name><surname>Badawy</surname><given-names>A</given-names></name><name><surname>State</surname><given-names>O</given-names></name><name><surname>Abdelgawad</surname><given-names>S</given-names></name></person-group><article-title>N-Acetyl cysteine and clomiphene citrate for induction of ovulation in polycystic ovary syndrome: a cross-over trial.</article-title><source>Acta Obstet Gynecol Scand</source><year>2007</year><volume>86</volume><fpage>218</fpage><lpage>222</lpage><pub-id pub-id-type="pmid">17364286</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name><surname>Balen</surname><given-names>AH</given-names></name></person-group><article-title>Ovulation induction in the management of anovulatory polycystic ovary syndrome.</article-title><source>Mol Cell Endocrinol</source><year>2013</year><volume>373</volume><fpage>77</fpage><lpage>82</lpage><pub-id pub-id-type="pmid">23084977</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name><surname>Baloglu</surname><given-names>E</given-names></name><name><surname>Senyigit</surname><given-names>ZA</given-names></name><name><surname>Karavana</surname><given-names>SY</given-names></name></person-group><article-title>Strategies to prolong the intravaginal residence time of drug delivery systems.</article-title><source>J Pharm Pharm Sci</source><year>2009</year><volume>12</volume><issue>3</issue><fpage>312</fpage><lpage>336</lpage><pub-id pub-id-type="pmid">20067707</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name><surname>Bernkop-Schn&#x000fc;rch</surname><given-names>A</given-names></name><name><surname>Hornof</surname><given-names>M</given-names></name></person-group><article-title>Intravaginal drug delivery systems design, challenges, and solutions.</article-title><source>Am J Drug Deliv</source><year>2003</year><volume>1</volume><fpage>241</fpage><lpage>254</lpage></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name><surname>Bonhoff</surname><given-names>AJ</given-names></name><name><surname>Naether</surname><given-names>OG</given-names></name><name><surname>Johannisson</surname><given-names>E</given-names></name></person-group><article-title>Effects of clomiphene citrate stimulation on endometrial structure in infertile women.</article-title><source>Hum Reprod</source><year>1996</year><volume>11</volume><fpage>844</fpage><lpage>849</lpage><pub-id pub-id-type="pmid">8671338</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal" publication-format="electronic"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>J</given-names></name><name><surname>Farquhar</surname><given-names>C</given-names></name><name><surname>Beck</surname><given-names>J</given-names></name><etal/></person-group><article-title>Clomiphene and antioestrogens for ovulation induction in PCOS.</article-title><source>Cochrane Database of Syst Rev</source><year>2009</year><volume>4</volume><elocation-id>CD002249</elocation-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>J</given-names></name><name><surname>Hooper</surname><given-names>G</given-names></name><name><surname>Kenyon</surname><given-names>CJ</given-names></name></person-group><article-title>Spreading and retention of vaginal formulations in postmenopausal women as assessed by gamma scintigraphy.</article-title><source>Pharm Res</source><year>1997</year><volume>14</volume><fpage>1073</fpage><lpage>1078</lpage><pub-id pub-id-type="pmid">9279891</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name><surname>Casper</surname><given-names>RF</given-names></name></person-group><article-title>It&#x02019;s time to pay attention to the endometrium.</article-title><source>Fertil Steril</source><year>2011</year><volume>96</volume><fpage>519</fpage><lpage>521</lpage><pub-id pub-id-type="pmid">21880272</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal" publication-format="electronic"><person-group person-group-type="author"><name><surname>Das</surname><given-names>V</given-names></name><name><surname>Agarwal</surname><given-names>A</given-names></name><name><surname>Pandey</surname><given-names>A</given-names></name><etal/></person-group><article-title>Evaluation of role of sildenafil in improving IUI success rates</article-title><source>Poster presentations/International Journal of Gynecology &#x00026; Obstetrics</source><year>2009</year><volume>107</volume><elocation-id>107S2 S413&#x02013;S729</elocation-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name><surname>Dehbashi</surname><given-names>S</given-names></name><name><surname>Parsanezhad</surname><given-names>ME</given-names></name><name><surname>Alborzi</surname><given-names>S</given-names></name><etal/></person-group><article-title>Effect of clomiphene citrate on endometrium thickness and echogenic patterns.</article-title><source>Int J Gynaecol Obstet</source><year>2003</year><volume>80</volume><fpage>49</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">12527460</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name><surname>Eijkemans</surname><given-names>MJ</given-names></name><name><surname>Imani</surname><given-names>B</given-names></name><name><surname>Mulders</surname><given-names>AG</given-names></name><etal/></person-group><article-title>High singleton live birth rate following classical ovulation induction in normogonadotropic anovulatory infertility (WHO 2).</article-title><source>Hum Reprod</source><year>2003</year><volume>18</volume><fpage>2357</fpage><lpage>2362</lpage><pub-id pub-id-type="pmid">14585887</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name><surname>Esmailzadeh</surname><given-names>S</given-names></name><name><surname>Faramarzi</surname><given-names>M</given-names></name></person-group><article-title>Endometrial thickness and pregnancy outcome after intrauterine insemination.</article-title><source>Fertil Steril</source><year>2007</year><volume>88</volume><fpage>432</fpage><lpage>437</lpage><pub-id pub-id-type="pmid">17434500</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name><surname>Fernandez</surname><given-names>H</given-names></name><name><surname>Morin-Surruca</surname><given-names>M</given-names></name><name><surname>Torre</surname><given-names>A</given-names></name><etal/></person-group><article-title>Ovarian drilling for surgical treatment of polycystic ovarian syndrome: a comprehensive review.</article-title><source>Reprod Biomed Online</source><year>2011</year><volume>22</volume><issue>6</issue><fpage>556</fpage><lpage>568</lpage><pub-id pub-id-type="pmid">21511534</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name><surname>Gleicher</surname><given-names>N</given-names></name><name><surname>Kim</surname><given-names>A</given-names></name><name><surname>Michaeli</surname><given-names>T</given-names></name><etal/></person-group><article-title>Pilot cohort study of granulocyte colony-stimulating factor in the treatment of unresponsive thin endometrium resistant to standard therapies.</article-title><source>Hum Reprod</source><year>2013</year><volume>28</volume><issue>1</issue><fpage>172</fpage><lpage>177</lpage><pub-id pub-id-type="pmid">23081869</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="book" publication-format="print"><person-group person-group-type="author"><name><surname>Grady</surname><given-names>D</given-names></name><name><surname>Cummings</surname><given-names>S</given-names></name><name><surname>Hulley</surname><given-names>S</given-names></name></person-group><source>Alternative trial design and implementation issues. In: Hulley S B, Cummings SR, Browner WS, Grady DG, Newman TB. Designing Clinical Research. Third edition.</source><publisher-loc>Philadelphia, USA</publisher-loc><publisher-name>Lippincott Williams &#x00026; Wilkins</publisher-name><year>2007</year><fpage>165</fpage><lpage>182</lpage></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="other" publication-format="electronic"><person-group person-group-type="author"><name><surname>Gutarra-Vilchez</surname><given-names>RB</given-names></name><name><surname>Urr&#x000fa;tia</surname><given-names>G</given-names></name><name><surname>Glujovsky</surname><given-names>D</given-names></name><etal/></person-group><article-title>Vasodilators for women undergoing fertility treatment.</article-title><source>Cochrane database Syst Rev</source><year>2014</year></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name><surname>Homburg</surname><given-names>R</given-names></name><name><surname>Hendriks</surname><given-names>ML</given-names></name><name><surname>K&#x000f6;nig</surname><given-names>TE</given-names></name><etal/></person-group><article-title>Clomifene citrate or low-dose FSH for the first-line treatment of infertile women with anovulation associated with polycystic ovary syndrome: a prospective randomized multinational study.</article-title><source>Hum Reprod</source><year>2012</year><volume>27</volume><fpage>468</fpage><lpage>473</lpage><pub-id pub-id-type="pmid">22128296</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name><surname>Hsu</surname><given-names>CC</given-names></name><name><surname>Kuo</surname><given-names>HC</given-names></name><name><surname>Wang</surname><given-names>ST</given-names></name><etal/></person-group><article-title>Interference with uterine blood flow by clomiphene citrate in women with unexplained infertility.</article-title><source>Obstet Gynecol</source><year>1995</year><volume>86</volume><issue>6</issue><fpage>917</fpage><lpage>921</lpage><pub-id pub-id-type="pmid">7501339</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name><surname>Kolibianakis</surname><given-names>EM</given-names></name><name><surname>Zikopoulos</surname><given-names>KA</given-names></name><name><surname>Fatemi</surname><given-names>HM</given-names></name><etal/></person-group><article-title>Endometrial thickness cannot predict ongoing pregnancy achievement in cycles stimulated with clomiphene citrate for intrauterine insemination.</article-title><source>Reprod Biomed Online</source><year>2004</year><volume>8</volume><fpage>115</fpage><lpage>118</lpage><pub-id pub-id-type="pmid">14759299</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name><surname>Malinova</surname><given-names>M</given-names></name><name><surname>Abouyta</surname><given-names>T</given-names></name><name><surname>Krasteva</surname><given-names>M</given-names></name></person-group><article-title>The effect of vaginal sildenafil citrate on uterine blood flow and endometrium in the infertile women.</article-title><source>Akush Ginekol (Sofiia)</source><year>2013</year><volume>52</volume><issue>1</issue><fpage>26</fpage><lpage>30</lpage></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name><surname>Merabet</surname><given-names>J</given-names></name><name><surname>Thompson</surname><given-names>D</given-names></name><name><surname>Saul et</surname><given-names>al</given-names></name></person-group><article-title>Advancing vaginal drug delivery.</article-title><source>Expert Opin Drug Deliv</source><year>2005</year><volume>2</volume><fpage>769</fpage><lpage>777</lpage><pub-id pub-id-type="pmid">16296801</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name><surname>Mitwally</surname><given-names>MF</given-names></name><name><surname>Casper</surname><given-names>RF</given-names></name></person-group><article-title>Potential of aromatase inhibitors for ovulation and superovulation induction in infertile women.</article-title><source>Drugs</source><year>2006</year><volume>66</volume><fpage>2149</fpage><lpage>2160</lpage><pub-id pub-id-type="pmid">17137400</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name><surname>Miwa</surname><given-names>I</given-names></name><name><surname>Tamura</surname><given-names>H</given-names></name><name><surname>Takasaki</surname><given-names>A</given-names></name><etal/></person-group><article-title>Pathophysiologic features of thin endometrium.</article-title><source>Fertil Steril</source><year>2009</year><volume>91</volume><issue>4</issue><fpage>998</fpage><lpage>1004</lpage><pub-id pub-id-type="pmid">18328483</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name><surname>Nakai</surname><given-names>A</given-names></name><name><surname>Yokota</surname><given-names>A</given-names></name><name><surname>Koshino</surname><given-names>T</given-names></name><etal/></person-group><article-title>Assessment of endometrial perfusion with Doppler ultrasound in spontaneous and stimulated menstrual cycles.</article-title><source>J Nippon Med Sch</source><year>2002</year><volume>69</volume><issue>4</issue><fpage>328</fpage><lpage>332</lpage><pub-id pub-id-type="pmid">12187364</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name><surname>Nakanrura</surname><given-names>Y</given-names></name><name><surname>Ono</surname><given-names>M</given-names></name><name><surname>YoShida</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Effects of clomiphene citrate on the endometrial thickness and echogenic pattern of the endometrium.</article-title><source>Fertil Steril</source><year>1997</year><volume>67</volume><fpage>256</fpage><lpage>259</lpage><pub-id pub-id-type="pmid">9022599</pub-id></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name><surname>Ng</surname><given-names>EH</given-names></name><name><surname>Chan</surname><given-names>CC</given-names></name><name><surname>Tang</surname><given-names>OS</given-names></name><etal/></person-group><article-title>The role of endometrial blood flow measured by three-dimensional power Doppler ultrasound in the prediction of pregnancy during in vitro fertilization treatment.</article-title><source>Eur J Obstet Gynecol Reprod Biol</source><year>2007</year><volume>135</volume><fpage>8</fpage><lpage>16</lpage><pub-id pub-id-type="pmid">17658677</pub-id></element-citation></ref><ref id="B31"><label>31</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name><surname>Palomba</surname><given-names>S</given-names></name><name><surname>Russo</surname><given-names>T</given-names></name><name><surname>Orio Jr</surname><given-names>F</given-names></name><etal/></person-group><article-title>Uterine effects of clomiphene citrate in women with polycystic ovary syndrome: a prospective controlled study.</article-title><source>Hum Reprod</source><year>2006</year><volume>21</volume><fpage>2823</fpage><lpage>2829</lpage><pub-id pub-id-type="pmid">16835214</pub-id></element-citation></ref><ref id="B32"><label>32</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name><surname>Reynolds</surname><given-names>K</given-names></name><name><surname>Khoury</surname><given-names>J</given-names></name><name><surname>Sosnowski</surname><given-names>J</given-names></name><etal/></person-group><article-title>Comparison of the effect of tamoxifen on endometrial thickness in women with thin endometrium (&#x0003c;7 mm) undergoing ovulation induction with clomiphene citrate.</article-title><source>Fertil Steril</source><year>2010</year><volume>93</volume><issue>6</issue><fpage>2091</fpage><lpage>2093</lpage><pub-id pub-id-type="pmid">19775686</pub-id></element-citation></ref><ref id="B33"><label>33</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name><surname>Richter</surname><given-names>KS</given-names></name><name><surname>Bugge</surname><given-names>KR</given-names></name><name><surname>Bromer</surname><given-names>JG</given-names></name><etal/></person-group><article-title>Relationship between endometrial thickness and embryo implantation, based on 1,294 cycles of in vitro fertilization with transfer of two blastocyst-stage embryos.</article-title><source>Fertil Steril</source><year>2007</year><volume>87</volume><fpage>53</fpage><lpage>59</lpage><pub-id pub-id-type="pmid">17081537</pub-id></element-citation></ref><ref id="B34"><label>34</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name><surname>Rogers</surname><given-names>PA</given-names></name><name><surname>Lederman</surname><given-names>F</given-names></name><name><surname>Taylor</surname><given-names>N</given-names></name></person-group><article-title>Endometrial microvascular growth in normal and dysfunctional states.</article-title><source>Hum Reprod Update</source><year>1998</year><volume>4</volume><fpage>503</fpage><lpage>538</lpage><pub-id pub-id-type="pmid">10027602</pub-id></element-citation></ref><ref id="B35"><label>35</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name><surname>Sakhavar</surname><given-names>N</given-names></name><name><surname>Kaveh</surname><given-names>M</given-names></name><name><surname>Sadegi</surname><given-names>K</given-names></name></person-group><article-title>The impact of letrozole versus clomiphene citrate on uterine blood flow in patients with unexplained infertility.</article-title><source>J Family Reprod Health</source><year>2014</year><volume>8</volume><issue>1</issue><fpage>1</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">24971126</pub-id></element-citation></ref><ref id="B36"><label>36</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name><surname>Senturk</surname><given-names>LM</given-names></name><name><surname>Erel</surname><given-names>CT</given-names></name></person-group><article-title>Thin endometrium in assisted reproductive technology.</article-title><source>Curr Opin Obstet Gynecol</source><year>2008</year><volume>3</volume><fpage>221</fpage><lpage>228</lpage></element-citation></ref><ref id="B37"><label>37</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name><surname>Sereepapong</surname><given-names>W</given-names></name><name><surname>Suwajanakorn</surname><given-names>S</given-names></name><name><surname>Triratanachat</surname><given-names>S</given-names></name><etal/></person-group><article-title>Effects of clomiphene citrate on the endometrium of regularly cycling women.</article-title><source>Fertil Steril</source><year>2000</year><volume>73</volume><fpage>287</fpage><lpage>291</lpage><pub-id pub-id-type="pmid">10685531</pub-id></element-citation></ref><ref id="B38"><label>38</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name><surname>Shahin</surname><given-names>AY</given-names></name></person-group><article-title>Endometrial sonographic characters predicting pregnancy following recurrent clomiphene induction in unexplained infertility.</article-title><source>Reprod Biomed Online</source><year>2008</year><volume>17</volume><fpage>795</fpage><lpage>802</lpage><pub-id pub-id-type="pmid">19079963</pub-id></element-citation></ref><ref id="B39"><label>39</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name><surname>Shanmugam</surname><given-names>S</given-names></name><name><surname>Kim</surname><given-names>YH</given-names></name><name><surname>Park</surname><given-names>JH</given-names></name><etal/></person-group><article-title>Sildenafil vaginal suppositories: preparation, characterization, in vitro and in vivo evaluation.</article-title><source>Drug Dev Ind Pharm</source><year>2014</year><volume>40</volume><issue>6</issue><fpage>803</fpage><lpage>812</lpage><pub-id pub-id-type="pmid">23781859</pub-id></element-citation></ref><ref id="B40"><label>40</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name><surname>Sher</surname><given-names>G</given-names></name><name><surname>Fisch</surname><given-names>JD</given-names></name></person-group><article-title>Effect of vaginal sildenafil citrate on the outcome of in vitro fertilization (IVF) after multiple IVF failures attributed to poor endometrial development.</article-title><source>Fertil Steril</source><year>2002</year><volume>78</volume><fpage>1073</fpage><lpage>1076</lpage><pub-id pub-id-type="pmid">12413996</pub-id></element-citation></ref><ref id="B41"><label>41</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name><surname>Sher</surname><given-names>G</given-names></name><name><surname>Fisch</surname><given-names>JD</given-names></name></person-group><article-title>Vaginal sildenafil citrate (Viagra): a preliminary report of a novel method to improve uterine artery blood flow and endometrial development in patients undergoing IVF.</article-title><source>Hum Reprod</source><year>2000</year><volume>15</volume><fpage>806</fpage><lpage>809</lpage><pub-id pub-id-type="pmid">10739824</pub-id></element-citation></ref><ref id="B42"><label>42</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name><surname>Takasaki</surname><given-names>A</given-names></name><name><surname>Tamura</surname><given-names>H</given-names></name><name><surname>Miwa</surname><given-names>I</given-names></name><etal/></person-group><article-title>Endometrial growth and uterine blood flow: a pilot study for improving endometrial thickness in the patients with a thin endometrium.</article-title><source>Fertil Steril</source><year>2010</year><volume>93</volume><issue>6</issue><fpage>1851</fpage><lpage>1858</lpage><pub-id pub-id-type="pmid">19200982</pub-id></element-citation></ref><ref id="B43"><label>43</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="given-only"><given-names>The ESHRE Capri Workshop Group</given-names></name></person-group><article-title>Health and fertility in World Health Organization type 2 anovulatory women.</article-title><source>Hum Reprod Update</source><year>2012</year><volume>18</volume><fpage>586</fpage><lpage>599</lpage><pub-id pub-id-type="pmid">22611175</pub-id></element-citation></ref><ref id="B44"><label>44</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="given-only"><given-names>The Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group</given-names></name></person-group><article-title>Consensus on infertility treatment related to polycystic ovary syndrome.</article-title><source>Human Reprod</source><year>2008</year><volume>23</volume><fpage>462</fpage><lpage>477</lpage></element-citation></ref><ref id="B45"><label>45</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name><surname>Van Santbrink</surname><given-names>EJ</given-names></name><name><surname>Fauser</surname><given-names>BC</given-names></name></person-group><article-title>Ovulation induction in normogonadotropic anovulation (PCOS) Best Pract Res.</article-title><source>Clin Endocrinol Metab</source><year>2006</year><volume>20</volume><issue>2</issue><fpage>261</fpage><lpage>270</lpage></element-citation></ref><ref id="B46"><label>46</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name><surname>Weiss</surname><given-names>NS</given-names></name><name><surname>Braam</surname><given-names>S</given-names></name><name><surname>K&#x000f6;nig</surname><given-names>TE</given-names></name><etal/></person-group><article-title>Hum Reprod</article-title><source>How long should we continue clomephine citrate in anovulatory women</source><year>2014</year><volume>29</volume><issue>11</issue><fpage>2482</fpage><lpage>2486</lpage></element-citation></ref></ref-list></back></article>